Drugs / Rondecabtagene autoleucel
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05826535 | May 2023 → Dec 2028 expected | large B-cell lymphoma, non-Hodgkin lymphoma | Lyell Immunopharma, Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07188558 | Jan 2026 → Dec 2029 expected | diffuse large B-cell lymphoma, large B-cell lymphoma | Lyell Immunopharma, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-12 | Lyell Immunopharma, Inc. | Results Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress lyell.com ↗
With over 100 patients treated, ronde-cel continues to show a consistent and manageable safety profile, supporting the potential for outpatient administration. |
All press releases naming this drug 2 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rondecabtagene autoleucel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07188558 ↗ |
| Known as | LYL314 | “rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in...” NCT05826535 ↗ |
| Known as | ronde-cel | “rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in...” NCT05826535 ↗1“This Phase 3 study compares rondecabtagene autoleucel (ronde-cel, a dual-targeting CD19/CD20 CAR T-cell therapy)” NCT07188558 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy” NCT05826535 ↗ |
| Route | Intravenous | “single administration of CAR transduced autologous T-cells administered intravenously” NCT05826535 ↗ |
| Target | CD19 | “dual-targeting CD19/CD20 CAR T-cell product candidate” NCT07188558 ↗ |